CA3243526A1 - THERAGNOSTICS FOLATE CONJUGATES - Google Patents
THERAGNOSTICS FOLATE CONJUGATESInfo
- Publication number
- CA3243526A1 CA3243526A1 CA3243526A CA3243526A CA3243526A1 CA 3243526 A1 CA3243526 A1 CA 3243526A1 CA 3243526 A CA3243526 A CA 3243526A CA 3243526 A CA3243526 A CA 3243526A CA 3243526 A1 CA3243526 A1 CA 3243526A1
- Authority
- CA
- Canada
- Prior art keywords
- compound according
- radiometal
- compound
- dota
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22154653 | 2022-02-01 | ||
| EP22154653.4 | 2022-02-01 | ||
| PCT/EP2023/052116 WO2023148115A1 (en) | 2022-02-01 | 2023-01-30 | Theragnostic folate conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3243526A1 true CA3243526A1 (en) | 2023-08-10 |
Family
ID=80119142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3243526A Pending CA3243526A1 (en) | 2022-02-01 | 2023-01-30 | THERAGNOSTICS FOLATE CONJUGATES |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250108138A1 (enExample) |
| EP (1) | EP4472676A1 (enExample) |
| JP (1) | JP2025504028A (enExample) |
| KR (1) | KR20240142514A (enExample) |
| CN (1) | CN118660723A (enExample) |
| AU (1) | AU2023214599A1 (enExample) |
| CA (1) | CA3243526A1 (enExample) |
| IL (1) | IL314507A (enExample) |
| WO (1) | WO2023148115A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025220711A1 (ja) * | 2024-04-17 | 2025-10-23 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物 |
| WO2026014283A1 (ja) * | 2024-07-09 | 2026-01-15 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物 |
-
2023
- 2023-01-30 CA CA3243526A patent/CA3243526A1/en active Pending
- 2023-01-30 JP JP2024544934A patent/JP2025504028A/ja active Pending
- 2023-01-30 WO PCT/EP2023/052116 patent/WO2023148115A1/en not_active Ceased
- 2023-01-30 KR KR1020247028953A patent/KR20240142514A/ko active Pending
- 2023-01-30 AU AU2023214599A patent/AU2023214599A1/en active Pending
- 2023-01-30 IL IL314507A patent/IL314507A/en unknown
- 2023-01-30 CN CN202380019559.6A patent/CN118660723A/zh active Pending
- 2023-01-30 US US18/834,637 patent/US20250108138A1/en active Pending
- 2023-01-30 EP EP23702011.0A patent/EP4472676A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023214599A1 (en) | 2024-09-19 |
| IL314507A (en) | 2024-09-01 |
| CN118660723A (zh) | 2024-09-17 |
| US20250108138A1 (en) | 2025-04-03 |
| JP2025504028A (ja) | 2025-02-06 |
| EP4472676A1 (en) | 2024-12-11 |
| KR20240142514A (ko) | 2024-09-30 |
| WO2023148115A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2990974T3 (es) | Conjugados de folato de entidades fijadoras de albúmina | |
| AU2014336638B2 (en) | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| JP2002515462A (ja) | 診断および治療用途に用いるホレート誘導化金属錯体 | |
| CN113573742A (zh) | 新型肿瘤抗原结合剂及其用途 | |
| EP2948186A1 (en) | Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides | |
| US20250108138A1 (en) | Theragnostic folate conjugates | |
| WO2026040780A1 (zh) | 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 | |
| Ruser et al. | Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111 | |
| US20250127938A1 (en) | Theragnostic folate conjugates | |
| WO2025195225A1 (zh) | 一种靶向fgl1的多肽及其应用 | |
| US20250339568A1 (en) | Precursor and radiotracer for neuroendocrine theranostics | |
| HK40110380A (zh) | 治疗诊断学叶酸酯缀合物 | |
| HK40109744A (zh) | 治疗诊断学叶酸酯缀合物 | |
| JP2024530057A (ja) | ネトリン－１検出、コンパニオン検査及び放射線に基づく療法 | |
| EP4640240A1 (en) | Peptide-based radiopharmaceuticals for non-invasive imaging of the functional liver reserve | |
| EP4282439A1 (en) | Radioisotope labeled sstr2-agonists with linkers | |
| KR20250011145A (ko) | 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드 | |
| CN121889176A (zh) | 用于体内定向pd-l1表达的功能化肽 | |
| HK40054611A (en) | Novel tumor antigen binding agents and uses thereof | |
| Jackson et al. | Molecular Imaging of Breast Cancer Tissue via Site-Directed Radiopharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240730 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240731 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240731 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241002 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |